Maximal domain for strategy-proof probabilistic rules in economies with one public good

We consider the problem of choosing a level of a public good on an interval of the real line among a group of agents. A probabilistic rule chooses a probability distribution over the interval for each preference profile. We investigate strategy-proof probabilistic rules in the case where distributions are compared based on stochastic dominance relations. First, on a minimally rich domain, we characterize the so-called probabilistic generalized median rules (Ehlers et al., 2002, Journal of Economic Theory 105: 408-434) by means of stochastic-dominance (sd) strategy-proofness and ontoness. Next, we study how much we can enlarge a domain to allow for the existence of sd-strategy-proof probabilistic rules that satisfy ontoness and the no-vetoer condition. We establish that the domain of convex preferences is the unique maximal domain including a minimally rich domain for these properties

A Characterization of the Uniform Rule with Several Commodities and Agents

We consider the problem of allocating infinitely divisible commodities among a group of agents. Especially, we focus on the case where there are several commodities to be allocated, and agents have continuous, strictly convex, and separable preferences. In this paper, we establish that the uniform rule is the only rule satisfying strategy-proofness, unanimity, symmetry, and nonbossiness.

Characterization of the uniform rule with several commodities and agents

We consider the problem of allocating infinitely divisible commodities among a group of agents. Especially, we focus on the case where there are several commodities to be allocated, and agents have continuous, strictly convex, and separable preferences. In this paper, we establish that the uniform rule is the only rule satisfying strategy-proofness, unanimity, symmetry, and nonbossiness

Identification and functional analysis of glutamine transporter inStreptococcus mutans

Background Streptococcus mutans, a biofilm-forming bacterium, possesses several transporters that function as import/export molecules. Among them, the PII protein family is composed of members that regulate glutamine synthesis in bacterial species. Objective In this study, we characterized the function of the glutamine transporter in S. mutans MT8148. Methods The SMU.732 gene, corresponding to glnP in S. mutans, is homologous to the glutamine transporter gene in Bacillus subtilis. We constructed a glnP-inactivated mutant strain (GEMR) and a complement strain (comp-GEMR) and evaluated their biological functions. Results Growth of GEMR was similar in the presence and absence of glutamine, whereas the growth rates of MT8148 and comp-GEMR were significantly lower in the presence of glutamine as compared to its absence. Furthermore, biofilms formed by MT8148 and comp-GEMR were significantly thicker than that formed by GEMR, while the GEMR strain showed a significantly lower survival rate in an acidic environment than the other strains. Addition of n-phenyl-2-naphthylamine, used to label of the membrane, led to increased fluorescence intensity of MT8148 and GEMR, albeit that was significantly lower in the latter. Conclusions These results suggest that glnP is associated with glutamine transport in S. mutans, especially the import of glutamine involved in biofilm formation

Polarization-induced photovoltaic effects in Nd-doped BiFeO 3 ferroelectric thin films

BiFeO 3 (BNF) thin films were fabricated on SrRuO 3 (SRO)-coated (100) Nb-doped SrTiO 3 subtrates by pulsed laser deposition, and nondoped BiFeO 3 (BFO) thin films were also fabricated similarly for comparison. Then, Nd-doping effects on ferroelectric and photovoltaic properties were evaluated. Polarization-induced photovoltaic effects were observed in both the BFO and BNF solar cell structures with top and bottom electrodes under intense laser illumination. Using Au top electrodes, enhanced photovoltaic properties were observed in the BNF cell compared with the BFO cell. To improve the photovoltaic properties of the BNF cell, instead of the Au top electrodes, In-Sn-O (ITO) top electrodes were employed for the BNF cell. As a result, the photovoltaic properties were found to be markedly improved, resulting in an open circuit voltage of 0.81 V and a short circuit current density of 12.1 mA/cm2. © 2012 The Japan Society of Applied Physics

One-year morbidity and mortality in patients treated with standard-dose and low-dose apixaban after acute large vessel occlusion stroke

The version of record of this article, first published in Journal of Thrombosis and Thrombolysis, is available online at Publisher’s website: https://doi.org/10.1007/s11239-024-02954-7.Although low-dose direct oral anticoagulants (DOACs) are recommended for patients at high risk of bleeding complications, it remains unclear whether the dose reduction in real-world setting is also appropriate in patients after large-vessel occlusion (LVO) stroke. This study hypothesized that patients with atrial fibrillation (AF) and LVO receiving low-dose DOACs have an increased risk of ischemic and hemorrhagic events. The study aimed to assess 1 year morbidity and mortality in patients treated with standard-dose and low-dose apixaban after LVO stroke. A post hoc analysis was performed using the acute LVO registry data, which enrolled patients with AF and LVO who received apixaban within 14 days of stroke onset. The incidences of ischemic events (ischemic stroke, acute coronary syndrome, acute myocardial infarction, and systemic embolism), major bleeding events, and death from any cause were compared between patients receiving standard- and low-dose apixaban. Of 643 patients diagnosed with LVO, 307 (47.7%) received low-dose apixaban. After adjustment for clinically relevant variables, no significant differences were observed in the incidence of ischemic events (adjusted hazard ratio [aHR]: 2.12, 95% confidence interval [CI] 0.75–6.02), major bleeding events (aHR: 1.17, 95% CI 0.50–2.73), and death from any cause (aHR: 1.95, 95% CI 0.78–4.89) between patients receiving standard- and low-dose apixaban. No significant differences were observed in the incidence of ischemic events, major bleeding events, or death from any cause between patients with AF and LVO receiving standard- and low-dose apixaban